Research Paper Volume 11, Issue 9 pp 2551—2564

MiR-124 sensitizes cisplatin-induced cytotoxicity against CD133+ hepatocellular carcinoma cells by targeting SIRT1/ROS/JNK pathway

Figure 5. miR-124 enhanced the cisplatin-induced cytoxocity against CD133+ HCC cells through SIRT1/ROS pathway. (A) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL) and NAC (2 mM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cellular ROS was detected by flow cytometry. (B) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL) and NAC (2 mM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Cell viability was detected by MTT assays. *P<0.05 vs. cisplatin + NCO group. #P<0.05 vs. cisplatin + miR-124 group. (C) CD133+ HepG2 and Huh7 cells were treated with miR-124 (50 pmol/mL), SIRT1 plasmid (2 μg/mL) and NAC (2 mM). 24h later, these cells were treated with cisplatin (10 μM) for another 48 h. Flow cytometry analysis was then performed to detect the cell apoptotic rate. *P<0.05 vs. cisplatin + NCO group. #P<0.05 vs. cisplatin + miR-124 group.